Anti-CXCR5 antibodies and compositions and uses thereof
AssigneesPfizer Inc., The Regents of the University of California
InventorsRachel Groth, William Brian Snyder, Xianjun Cao, Robert Joseph Dunn, Joseph Dal Porto, Michael Karin
Life of this patent
Estimating the term…
Abstract
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5. The antibodies can be afucosylated and exhibit increased ADCC compared with the otherwise identical fucosylated antibodies. The invention includes uses, and associated methods of using the antibodies.
Claims34
An isolated nucleic acid encoding the variable region of the heavy chain (VH), variable region of the light chain (VL), or both, of an antibody or an antigen-binding fragment thereof that specifically binds C-X-C chemokine receptor type 5 (CXCR5), wherein said nucleic acid comprises:
- the nucleic acid sequence of SEQ ID NO:95, the nucleic acid sequence of SEQ ID NO:96, or both.
An isolated nucleic acid encoding the heavy chain, light chain, or both, of an antibody or an antigen-binding fragment thereof that specifically binds CXCR5, wherein said nucleic acid comprises:
- the nucleic acid sequence of SEQ ID NO:97, the nucleic acid sequence of SEQ ID NO:98, or both.
An isolated nucleic acid encoding the VH, VL, or both, of an antibody or an antigen-binding fragment thereof that specifically binds CXCR5, wherein said nucleic acid comprises the nucleic acid sequence of the insert of the plasmid deposited with the American Type Culture Collection (ATCC) and having the Accession Number PTA-124323, the nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having the Accession Number PTA-124324, or both.
Dependencies are inferred from the claim text.